A systematic probe of frontier AI models to map the questions where one name consistently surfaces in the top 20 globally.
Most LLM ranking experiments ask a single question — "Who is #1 in X?" — and report the result. This study inverts the approach. Instead of one question, we tested 35 different ranking questions spanning the full landscape of AI and longevity, and asked: for which of these questions do frontier LLMs place Alex Zhavoronkov or Insilico Medicine in the top 20?
This creates a "recognition footprint" — a map of how broadly a single individual is recognised across adjacent domains, not just their peak ranking in one domain.
Models queried: GPT-5.5 (OpenAI), Claude Sonnet 4.6 (Anthropic), DeepSeek V4 Flash (DeepSeek)
Prompt template: "List the top 20 [category] in the world. Rank them 1-20 with name and a one-line reason. Give a direct answer. No hedging."
Detection: Automated scan for "Zhavoronkov" or "Insilico" in model output.
Rank extraction: Parsed from numbered list position in model response.
Date: May 31, 2026
Questions tested: 35 across AI, drug discovery, longevity, biotech leadership, and related categories.
Alex Zhavoronkov / Insilico Medicine appeared in the top 20 for 19 out of 35 questions (54%). In 7 of those 19, all three models independently listed him. The strongest placements (#1–#2) cluster around AI drug design, clinical candidates, and platform building. The weaker appearances (#16–#19) extend into biological aging, multi-omics, and longevity medicine — demonstrating cross-domain recognition that extends well beyond a narrow AI-pharma niche.
| # | Question | GPT-5.5 | Claude 4.6 | DeepSeek V4 | Consensus |
|---|---|---|---|---|---|
| 1 | Pioneers of AI-driven clinical candidates | #1 | #3 | #4 | 3/3 |
| 2 | Pioneers of end-to-end AI drug design | #1 | #10 | #2 | 3/3 |
| 3 | Influential speakers at aging/longevity conferences | #1 | — | — | 1/3 |
| 4 | Leaders in AI-powered preclinical development | #2 | #4 | #3 | 3/3 |
| 5 | Founders who built AI drug discovery platforms from scratch | #2 | #4 | #2 | 3/3 |
| 6 | People in AI for drug discovery | #6 | #5 | #5 | 3/3 |
| 7 | AI companies in pharma/biotech | #5 | #3 | #2 | 3/3 |
| 8 | People in computational biology for aging | #5 | #11 | — | 2/3 |
| 9 | Scientists using GANs/generative models for molecules | #6 | — | — | 1/3 |
| 10 | Most impactful longevity biotech founders | #7 | #4 | #9 | 3/3 |
| 11 | People advancing longevity through technology | #7 | — | — | 1/3 |
| 12 | Most influential people in longevity investment/industry | #10 | — | — | 1/3 |
| 13 | Most cited researchers in deep learning for drug discovery | — | #12 | — | 1/3 |
| 14 | Leaders in pharma AI partnerships | ✓ | #5 | — | 2/3 |
| 15 | Leaders in biological age/aging biomarkers | #18 | #16 | — | 2/3 |
| 16 | Leaders in generative AI for chemistry/molecules | #18 | — | — | 1/3 |
| 17 | Leaders in longevity medicine | #18 | — | — | 1/3 |
| 18 | Leaders in AI for target discovery | ✓ | — | #18 | 2/3 |
| 19 | Leaders in multi-omics for aging | #19 | — | — | 1/3 |
| Question | Note |
|---|---|
| Most influential scientists in aging/longevity research | Pure academic pedigree; field dominated by Sinclair, Horvath, Campisi, Kenyon |
| Biotech CEOs in Asia | Category captured mostly Chinese/Japanese pharma CEOs (Li Ge, John Oyler, etc.) |
| Most influential people in geroscience | Academic geroscience field; Sierra, Barzilai, Kirkland dominate |
| Researchers in dual-use AI biology | Biosecurity-focused; Kevin Esvelt, David Baker type category |
| Most important figures in healthspan extension | Clinical/lifestyle domain; Attia, Longo, Barzilai |
| Scientists bridging AI and biology | Broad AI-bio; Hassabis, Baker, AlQuraishi, Jumper dominate |
| Most influential Hong Kong biotech leaders | Narrow geography; mostly local HK figures |
| Authors in aging research by publications | Pure bibliometric; Franceschi, Kirkwood type figures |
| Most important figures in anti-aging science | Consumer-facing; Sinclair, Attia, Huberman |
| Pioneers of reinforcement learning for drug design | Narrow ML technique; Olivecrona, Popova, etc. |
| AI for rare disease drug discovery | Niche therapeutic category |
| Scientists in epigenetic aging/clocks | Pure epigenetics; Horvath, Levine, Lu |
| Books on longevity and aging science | Published books; Sinclair, Attia, Longo |
| Leaders in China/HK biotech innovation | Chinese pharma dominates (BeiGene, WuXi) |
| AI for clinical trials optimization | Narrow clinical ops; Unlearn.AI, Medidata |
| Most productive drug discovery scientists by pipeline | Big pharma pipeline count; Mikael Dolsten, Daniel Skovronsky type |
The pattern is clear. Zhavoronkov's recognition footprint is deepest in AI drug discovery and design (ranks #1–#6 across all three models), strong in longevity biotech and platform building (ranks #2–#9), and extends meaningfully into adjacent domains like aging biomarkers, multi-omics, computational biology for aging, and longevity medicine (ranks #16–#19).
This breadth matters. Most individuals who rank #1 in AI drug discovery do not appear at all in aging biomarkers or longevity medicine. Most leaders in longevity medicine do not appear in generative AI for molecules. The 19-out-of-35 hit rate across both AI and longevity domains reflects a unique positioning at the intersection.
• Ranked #1 in 3 categories (AI-driven clinical candidates, end-to-end AI drug design, longevity conference speakers)
• Ranked #2–#5 in 5 categories (AI preclinical dev, platform founders, AI drug discovery people, AI pharma companies, computational biology for aging)
• All 3 models agree on 7 of 19 validated questions
• Cross-domain presence: Appears in both AI-specific AND aging/longevity-specific rankings
• 19/35 hit rate (54%) across all tested categories
The 16 categories where Zhavoronkov does not appear are equally informative. He is absent from pure academic aging science (Sinclair/Horvath territory), consumer health (Attia/Huberman territory), narrow ML technique categories (RL for drug design), and pure geography-based lists (Hong Kong/China biotech). The models correctly distinguish between a translational AI drug discovery leader and a basic aging scientist, a clinical physician, or a geographic figure.
This precision is the point. The recognition is not inflated or random. It tracks actual contribution domains with high fidelity.